What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 6 months ago
#OP0002 #EULAR2022 What immune tests to monitor during pregnancy in #lupus? A meta-analysis found:
💠32% had a flare (new IS or Pred>9mg/d)
💠⬇️C3 and/or C4 in 1st Trimester predicted LN or SLE flare
Worth checking C3/C4 in each trimester @RheumNow https://t.co/fPEXwReK7u https://t.co/BX6fzKzfvC
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 6 months ago
#POS0183 #EULAR2022 Pooled analyses of 5 Belimumab RCTs showed better response vs PBO in those:
💠SLEDAI=>10
💠dsDNA+ve + ⬇️C3 and/ ⬇️C4
💠⬇️C3 and/ C4 pre-treatment
💠Response high regardless SDI, Steroid, #lupus duration
@RheumNow https://t.co/fLggazbRQu
Ashima Makol MD AshimaMakol
3 years 6 months ago
✨Localized #Scleroderma Pearls✨
#EULAR2022
Eosinophilic Fasciitis
👉Contractures wrists/ankles, rarely fingers
👉Mimics- #Lipodermatosclerosis #Panniculitis
👉GCs+MTX 1st line (IV in refractory🧐),MMF 2nd line
✅I add IVIg+/-UVA1 (pending logistics and insurance coverage!) https://t.co/ZErfLxgdxd
Richard Conway RichardPAConway
3 years 6 months ago
Hellamand et al. Sex differences in first TNFi response in AxSpA. Treatment efficacy (RR 0.85) and retention (58% vs 72% month 24) rates lower in females. @RheumNow #EULAR2022 OP0020 https://t.co/2IL88K7q40 https://t.co/hSJds5EJFK
Richard Conway RichardPAConway
3 years 6 months ago
TOFFIFE RCT in colchicine-resistant FMF. Tocilizumab normalises SAA and CRP/ESR with PGA response in 20-25%. Maybe response criteria too strict, or maybe TCZ only effective for subgroup of patients @RheumNow #EULAR2022 OP0043 https://t.co/kNs8DMzXFB https://t.co/QMDk1IUkjx
Richard Conway RichardPAConway
3 years 6 months ago
Adami et al on risk of RMDs with air pollution. Mainly RA - OR 1.4 for PM10, 1.6 for PM2.5 @RheumNow #EULAR2022 OP0071 https://t.co/zDr2jMsIWv https://t.co/f0Y2rQxWRD
Janet Pope Janetbirdope
3 years 6 months ago
Can you train #dermatologists to do ultrasound to detect #PsA if pt has joint pain. POCUS of up to 3 painful joints. US ⬆️derm suspicion of PsA- but this is not feasible in busy offices and no reimbursement @RheumNow #EULAR2022 @eular_org OP0029 https://t.co/9a3gDgIBp0
Eric Dein ericdeinmd
3 years 6 months ago
#EULAR2022 TREAT-EARLIER OP0700
Arthralgia + subclinical inflammation in MRI without RA, treated with MTX + depo steroid injection
▶️In High risk patients, delayed development of synovitis, but does not prevent in long-term
▶️Reduction in disease burden on MTX Rx
@RheumNow https://t.co/SKlqMQQTui
Richard Conway RichardPAConway
3 years 6 months ago
Zhao et al. Infection risk is ⬆️ in incident AAV. aHR 3.8 for first infection and 3.8 for infectious mortality. 3.2 fold increase in number infections. @RheumNow #EULAR2022 OP0093 https://t.co/LSe4vJqZym https://t.co/tNqI2m30SD
Richard Conway RichardPAConway
3 years 6 months ago
MIRACLE (love it!) study. High (max tolerated up to 25mg) vs low dose (6-8mg) MTX in combo with ADA in MTX-IR. Low dose non-inferior with better safety. Japanese population so may not be generalisable. @RheumNow #EULAR2022 OP0062 https://t.co/l3CfzzM7mi https://t.co/lkjuoqLY56
Richard Conway RichardPAConway
3 years 6 months ago
Krijbolder et al on MTX to prevent RA in clinically suspect arthralgia. No effect on arthritis free survival (80 vs 82%). Some delay in RA onset in high-risk group. But there was a sustained improvement in symptoms in MTX group @RheumNow #EULAR2022 OP0070 https://t.co/0CPIP51yQd https://t.co/kWNmw1YzrH
Richard Conway RichardPAConway
3 years 6 months ago
Bimekizumab (dual 17A/17F inhibitor) RCT in AS. ASAS40 45% vs 23% at week 16. All secondary clinical and imaging endpoints also + @RheumNow #EULAR2022 OP0019 https://t.co/RiZ7Divap3 https://t.co/ushogL5TaX
Robert B Chao, MD doctorRBC
3 years 6 months ago
How do we treat fatigue in our PsA patients? Guselkumab PsA trials showed systemic disease activity/function, joint manifestations, and skin involvement accounted for 62% of variability in fatigue. How do we account for the other 38%?
@RheumNow #EULAR2022 ABST#OP0025
David Liew drdavidliew
3 years 6 months ago
Early RA - does the biologic matter?
NORD-STAR: largely seropos, high CRP early RA
Perhaps unsurprising abatacept shone vs TNFi or TCZ
One of the few pt subgroups with plausible rationale & some data for comparative advantage. Shame it’s less & less common?
#EULAR2022 @RheumNow https://t.co/CrOILKVpIp
Richard Conway RichardPAConway
3 years 6 months ago
Combined Nordic registry data on demyelination and inflammatory neuropathy with TNFi. Demyelination 2-3 times higher in SpA vs RA. No difference between ETN and monoclonals. @RheumNow #EULAR2022 OP0060 https://t.co/SK9s7aVaZk https://t.co/hZ5VaoTe4X
Poster Hall